← All trials
NCT00071032
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2003
- Primary completion
- May 1, 2009
- Completion date
- May 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 2016
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Rutgers UniversityLead sponsor
- University of MarylandOverall official - principal investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Rutgers UniversityReponsible party - principal investigator
- University of Medicine and Dentistry of New JerseyStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.